Motilal Oswal Research Desk has identified Emcure Pharmaceuticals and Cholamandalam Investment as top picks for the trading week starting September 15, 2026. Both stocks show significant growth potential.

  • Motilal Oswal recommends Emcure Pharmaceuticals and Cholamandalam Investment.
  • Target upsides are estimated at 16% and 17% respectively.
  • Growth is driven by pharmaceutical expansion and financial diversification.

For the upcoming trading week starting September 15, 2026, market analysts have pinpointed specific opportunities for investors seeking growth. According to the Motilal Oswal Wealth Management Research Desk, two specific stocks—Emcure Pharmaceuticals and Cholamandalam Investment & Finance Company Ltd—stand out as top recommendations for the holiday-shortened week.

Top Stock Picks at a Glance

The research desk has provided specific price targets and expected percentage increases for these entities:

Read Also:Collections Under RBI's Dollar Swap Scheme Surpass $72.8 Billion
Stock NameCMP (Rs)Target Price (Rs)Upside (%)
Emcure Pharmaceuticals1975230016%
Cholamandalam Investment1843216017%

Emcure Pharmaceuticals: Expanding Global Footprint

Emcure Pharmaceuticals is aggressively strengthening its presence across Europe, Canada, and other Rest of World (ROW) markets. The company’s performance in Q1FY27 was robust, with revenue growing 22.8% YoY to INR 25.8bn and adjusted PAT rising 34% YoY to INR 2.9bn. While gross margins saw a slight contraction, the management's focus on niche products and a strong commercial network is expected to drive mid-teen revenue growth through FY27.

Cholamandalam Investment: The Shift to Diversified Lending

Cholamandalam Investment (CIFC) is undergoing a strategic transformation. Moving beyond its roots as a vehicle-finance specialist, it is evolving into a comprehensive lending platform. By integrating mortgage, gold loans, consumer finance, and MSME lending, the company is building a higher-yielding and more resilient earnings stream. This diversification is expected to bolster its Return on Assets (RoA) to approximately 2.7% by FY27.

Why This Matters

BozokMedia analysis shows that the current market trend favors companies that can successfully navigate global demand shifts and domestic credit diversification. Emcure’s international trajectory and Cholamandalam’s pivot toward diversified credit products represent a sophisticated approach to mitigating sector-specific risks while capturing high-growth segments.

Strategic diversification in both product mix and geographic reach is the hallmark of resilient growth in the current economic landscape.
Did You Know?: Diversified financial institutions often exhibit lower volatility during economic downturns compared to specialized lenders.

Frequently Asked Questions

1. What is the primary driver for Emcure's growth?
Its expansion into international markets like Europe and Canada is the key catalyst.

2. Why is Cholamandalam's diversification important?
It reduces reliance on the vehicle finance sector and opens up higher-margin opportunities in mortgages and MSME loans.